Yoo, Seong-Keun http://orcid.org/0000-0002-8749-7050
Chowell, Diego
Valero, Cristina
Morris, Luc G. T. http://orcid.org/0000-0002-4417-2280
Chan, Timothy A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35 CA232097)
Article History
Received: 6 October 2021
Accepted: 24 February 2022
First Online: 7 April 2022
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca, and An2H. T.A.C., L.G.T.M., and D.C. hold ownership of intellectual property on using tumor mutation burden to predict immunotherapy response, with a pending patent, which has been licensed to PGDx. The remaining authors declare no competing interests.